retatrutide and cagrilintide 15mg 5mg Three new #obesity drugshigh dose semaglutide, semaglutide plus cagrilintide, and oral orforglipronmay soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how Cagrilintide, an amylin analogue, is a promising medication for weight loss by enhancing satiety, delaying gastric emptying, and suppressing appetite. In my patients, I have also seen increased Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet obesity gutsandgrowth Page 2